Compare CTMX & ENVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CTMX | ENVX |
|---|---|---|
| Founded | 2008 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Miscellaneous |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 716.9M | 612.3M |
| IPO Year | 2015 | 2020 |
| Metric | CTMX | ENVX |
|---|---|---|
| Price | $2.04 | $1.84 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 12 |
| Target Price | ★ $12.25 | $9.75 |
| AVG Volume (30 Days) | 5.0M | ★ 9.5M |
| Earning Date | 11-05-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 40.94 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $76,201,000.00 | $31,821,000.00 |
| Revenue This Year | N/A | $23.31 |
| Revenue Next Year | $14.69 | $93.03 |
| P/E Ratio | $22.58 | ★ N/A |
| Revenue Growth | N/A | ★ 37.91 |
| 52 Week Low | $1.90 | $2.19 |
| 52 Week High | $8.21 | $9.19 |
| Indicator | CTMX | ENVX |
|---|---|---|
| Relative Strength Index (RSI) | 39.98 | 33.68 |
| Support Level | N/A | N/A |
| Resistance Level | $2.61 | $3.01 |
| Average True Range (ATR) | 0.19 | 0.35 |
| MACD | -0.00 | -0.08 |
| Stochastic Oscillator | 30.77 | 4.76 |
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
Enovix Corp is engaged in designing, developing, manufacturing, and commercializing Lithium-ion, or Li-ion, battery cells. It uses BreakFlow and Encapsulation technologies to manufacture high capacity and resilient batteries. The company's product portfolio comprises power disc batteries, flexible lithium-ion polymer batteries, superior lithium-ion polymer batteries, active silicon lithium-ion cells, and others. Geographically, the company generates maximum revenue from its customers in South Korea, followed by Switzerland, the United States, Norway, Taiwan, and other regions.